Optimization of M2e cassette amino acid composition for the development of universal influenza vaccine

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The development of a universal influenza vaccine with a wide spectrum and duration of action is one of the serious public health problems. This study is dedicated to optimization of an immunogen covering the M2e epitopes of influenza A viruses circulating in the natural reservoir, as well as the creation of a prototype of a universal influenza vaccine with subsequent quantitative and qualitative assessment of the induced anti-M2e responses in ferrets.

Full Text

Restricted Access

About the authors

Daria А. Mezhenskaya

Institute of Experimental Medicine

Author for correspondence.
Email: dasmez@iemspb.ru
ORCID iD: 0000-0001-6922-7682
SPIN-code: 5799-8802

Junior Reseacher of Laboratory of Immunology and Prevention of Viral Infections, A.A. Smorodintsev Department of Virology

Russian Federation, Saint Petersburg

Irina N. Isakova-Sivak

Institute of Experimental Medicine

Email: isakova.sivak@gmail.com
ORCID iD: 0000-0002-2801-1508
SPIN-code: 3469-3600

Dr. Sci. (Biol.), Head of Laboratory of Immunology and Prevention of Viral Infections, A.A. Smorodintsev Department of Virology

Russian Federation, Saint Petersburg

Anastasiya E. Katelnikova

Institure of Preclinical Research

Email: katelnikova.ae@doclinika.ru
ORCID iD: 0000-0003-3203-9869
SPIN-code: 7473-6070

PhD

Russian Federation, Leningrad Region, Kuzmolovsky

Larisa G. Rudenko

Institute of Experimental Medicine

Email: vaccine@mail.ru
ORCID iD: 0000-0002-0107-9959
SPIN-code: 4181-1372

Dr. Sci. (Med.), Professor, Head of the A.A. Smorodintsev Department of Virology

Russian Federation, Saint Petersburg

References

  1. Deng L, Cho KJ, Fiers W, Saelens X. M2e-based universal influenza a vaccines. Vaccines (Basel). 2015;3(1):105–136. doi: 10.3390/vaccines3010105
  2. FuruseY, Suzuki A, Kamigaki T, Oshitani H. Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virol J. 2009;(6):67. doi: 10.1186/1743-422X-6-67
  3. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi ATJ. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002;83(Pt 8):1851–1859. doi: 10.1099/0022-1317-83-8-1851
  4. Liu W, Zou P, Chen YH. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett. 2004;93(2–3):131–136. doi: 10.1016/j.imlet.2004.03.003
  5. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol. 1988;62(8):2762–2772. doi: 10.1128/JVI.62.8.2762-2772.1988

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Scheme of 4M2e cassette

Download (89KB)
3. Fig. 2. Serum M2e IgG level after vaccination (a) and level of antibody binding with various antigens (b). LAIV – live attenuated influenza vaccine; PBS — phosphate buffered saline. Data were analyzed by one-way ANOVA with Tukey’s post-hoc multiple analyses test (* p < 0.05; ** p < 0.01; *** p < 0.001)

Download (150KB)

Copyright (c) 2021 Mezhenskaya D.А., Isakova-Sivak I.N., Katelnikova A.E., Rudenko L.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies